Dexcom (DXCM) Cost of Revenue (2010 - 2026)

Dexcom (DXCM) has reported Cost of Revenue for 17 consecutive years, with $478.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 2.16% year-over-year to $478.4 million in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 5.15% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 16.64% from the prior year.
• Cost of Revenue was $478.4 million for Q2 2026 at Dexcom, up from $441.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $478.4 million in Q2 2026 and troughed at $230.7 million in Q1 2022.
• A 5-year average of $374.2 million and a median of $377.8 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 43.2% in 2022 and dropped 1.21% in 2026, its largest moves.
• Over 5 years, Cost of Revenue stood at $273.9 million in 2022, then surged by 37.97% to $377.9 million in 2023, then climbed by 21.12% to $457.7 million in 2024, then climbed by 2.01% to $466.9 million in 2025, then rose by 2.46% to $478.4 million in 2026.
• The last three Cost of Revenue figures came in at $478.4 million (Q2 2026), $441.6 million (Q1 2026), and $466.9 million (Q4 2025), per Business Quant data.